Aveo Pharmaceuticals (NASDAQ:AVEO) shares traded 2.47% up during most recent session to reach at the closing price of $2.9. The stock exchanged hands 5.34 Million shares versus average trading capacity of 1.84 Million shares, yielding a market cap of $344.64 Million. Wall Street analysts covering the stock are projecting that the stock will reach $5.67 within the next 52-weeks. The mean target projections are based on 3 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Aveo Pharmaceuticals (NASDAQ:AVEO) high price target of $7 and with a conservative view have low price target of $5.
Seaport Global “Initiates Coverage On” Aveo Pharmaceuticals (NASDAQ:AVEO) in a research note issued to investors on 10/06/17 to Buy with price target of $7.
Additionally on 5/19/16 PiperJaffray “Initiates Coverage on” Aveo Pharmaceuticals (NASDAQ:AVEO) to Overweight and on 3/30/16 FBR Capital “Initiates Coverage on” the stock to Outperform. Furthermore on 3/09/15 RBC Capital “Upgrades” the stock to Sector Perform at $3.
On the other hand the company has Relative Strength Index (RSI 14) of 76.03 along with Average True Range (ATR 14) of 0.16, Consequently Aveo Pharmaceuticals (NASDAQ:AVEO)’s weekly and monthly volatility is 8.64%, 6.33% respectively. The company’s beta value is at 1.62.
In terms of Buy, Sell or Hold recommendations, Aveo Pharmaceuticals (NASDAQ:AVEO) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Aveo Pharmaceuticals (NASDAQ:AVEO)’s minimum EPS for the current quarter is at $-0.07 and can go high up to $-0.06. The consensus mean EPS for the current quarter is at $-0.06 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.3 earnings per share for the same quarter during last year.
Previously Aveo Pharmaceuticals (NASDAQ:AVEO) reported $-0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.07 by $-0.01. The company posted an earnings surprise of -14.3%.
Aveo Pharmaceuticals (NASDAQ:AVEO)’s revenue estimates for the current quarter are $1.35 Million according to 2 number of analysts, for the current quarter the company has high revenue estimates of $1.5 Million in contradiction of low revenue estimates of $1.2 Million. For the current year the company’s revenue estimates are $6.13 Million compared to low analyst estimates of $3.9 Million and high estimates of $7.4 Million according to 3 number of analysts.
Currently Aveo Pharmaceuticals (NASDAQ:AVEO)’s shares owned by insiders are 0.85%, whereas shares owned by institutional owners are 51.8%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0.01%.
Aveo Pharmaceuticals (NASDAQ:AVEO)’s trailing twelve month revenues are $6.1 Million, whereas its price to sales ratio for the same period is 56.5. Its book value per share for the most recent quarter is $-0.42 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.23, however its price to cash per share ratio for the same period is 12.76. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.